Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I RO5429083 in advanced CD44-expressing solid tumors with imaging sub-study
NL-OMON39242Phase 1Active, not recruiting
- Sponsor
- Roche
- Start
- Jun 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of RG7356 in Nonhematologic neoplasms and Non-hematologic malignancy (3 arms), sponsored by Roche. Primary endpoints: Pharmacokinetics of RO5429083, Safety and tolerability including maximum tolerated dose or optimal biological dose and 4 more. Started Jun 2011; status: active, not recruiting.
02
Drugs
RG7356
03
Conditions
Nonhematologic neoplasmsNon-hematologic malignancy
Beyond the preview
Go deeper on NL-OMON39242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39242.